Posted: 12 March 2024
Cynata Therapeutics (ASX:CYP) has also updated the market on the progress of its diabetic foot ulcers clinical trial.
Cynata said it has completed its initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in DFU, up to the 10-week follow-up time point.
Results show that the median percentage reduction in wound surface area in patients taking CYP-006TK group after 10 weeks was 87.6%, compared to 51.1% in the control group.
For clarity, a 100% reduction in wound surface area means complete wound healing.
These findings are consistent with the results observed from the first six patients enrolled in this trial up to Day 28, which were released in April 2023.
“These initial results are very promising, and consistent with the previous data readout,” said Dr Jolanta Airey, Cynata’s chief medical officer.
“We look forward to completing enrolment in the near future, which will take us a step closer to our objective of demonstrating safety and efficacy of CYP-006TK in DFU.”
